Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000128681 | SCV000332318 | pathogenic | not provided | 2017-05-17 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000128681 | SCV000521269 | pathogenic | not provided | 2021-07-14 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a damaging effect showing the variant to significantly inhibit formation of strong binding actomyosin disruptive to the ATPase cycle, impaired activation of contractility, and reduction in thin filament activation (Marttila et al., 2012; Karpicheva et al., 2013; Karpicheva et al., 2014); Missense variants in this gene are often considered pathogenic (Stenson et al., 2014); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24692096, 22084935, 11738357, 31321302, 24077912, 27535533, 23689010, 24657080) |
Invitae | RCV000531827 | SCV000630167 | pathogenic | Arthrogryposis, distal, type 1A | 2022-03-18 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 12462). For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects TPM2 function (PMID: 22084935, 23689010, 23886664, 24657080). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This missense change has been observed in individual(s) with congenital fiber type disproportion (CFTD), distal arthrogryposis (DA) and nemaline myopathy (NM) (PMID: 11738357, 24692096). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 117 of the TPM2 protein (p.Glu117Lys). |
OMIM | RCV000013278 | SCV000033525 | pathogenic | Congenital myopathy 23 | 2002-02-01 | no assertion criteria provided | literature only | |
Gene |
RCV000013278 | SCV000058547 | not provided | Congenital myopathy 23 | no assertion provided | literature only | ||
TPM2 homepage - |
RCV000128681 | SCV000172321 | not provided | not provided | no assertion provided | not provided |